Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus SODIUM SULAMYD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus SODIUM SULAMYD.
BENSULFOID vs SODIUM SULAMYD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
Sodium sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Bensulfoid: not a recognized drug. No data available.
1-2 drops of 10% or 15% solution into affected eye(s) every 2-3 hours initially, tapered as infection resolves; ophthalmic ointment: apply 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
7-13 hours (prolonged in renal impairment; in anuria up to 22-50 hours)
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Renal excretion of unchanged drug (approximately 70-100%) via glomerular filtration and tubular secretion; minor biliary/fecal elimination (<5%)
Category C
Category C
Topical Antibiotic
Topical Antibiotic